TY - JOUR
T1 - Cyclin G1 induces maladaptive proximal tubule cell dedifferentiation and renal fibrosis through CDK5 activation
AU - Taguchi, Kensei
AU - Elias, Bertha C.
AU - Sugahara, Sho
AU - Sant, Snehal
AU - Freedman, Benjamin S.
AU - Waikar, Sushrut S.
AU - Pozzi, Ambra
AU - Zent, Roy
AU - Harris, Raymond C.
AU - Parikh, Samir M.
AU - Brooks, Craig R.
N1 - Funding Information:
We thank Snorri Thorgeirsson at the National Cancer Institute for the use of the CG1-KO mice and Vanderbilt Cell Imaging Shared Resource and Nikon Center of Excellence (supported by NIH grants DK020593, CA68485, DK20593, DK58404, DK59637, and EY08126). We thank N. Yabuta and N. Nojima, Osaka University Research Institute for Microbial Diseases, Japan, for the gift of the CG1 plasmids. We thank Ramila Gulieva, Max Frank, and Arjun Sen (Freedman lab) for technical assistance with organoid experiments. This work was supported by US NIH grants DK121101 (to CRB), P30-DK114809 (to AP, RCH, and RZ), DK069921, DK088327, and DK127589 (to RZ), R01-DK119212 (to AP), and 5UC2DK126006, R01DK117914, and U01DK127553 (to BSF); American Heart Association grant 20POST35200221 (to KT); Department of Veterans Affairs award I01 BX002196 (to RZ); and Department of Veterans Affairs Merit Reviews award 1I01BX002025 (to AP). AP is the recipient of a Department of Veterans Affairs Senior Research Career Scientist Award.
Funding Information:
Authorship note: KT and BCE contributed equally to this work. Conflict of interest: CRB reports having ownership interest in DermYoung LLC. SSW reports grant support from Johnson & Johnson (J&J) and Vertex. BSF is an inventor on patents and patent applications related to kidney organoid differentiation and disease modeling (“Three-dimensional differentiation of epiblast spheroids into kidney tubular organoids modeling human microphysiology, toxicology, and morphogenesis” [Japan, US, and Australia], licensed to STEMCELL Technologies; “High-throughput automation of organoids for identifying therapeutic strategies” [PTC patent application pending]; “Systems and methods for characterizing pathophysiology” [PTC patent application pending]. In the last 24 months, SMP has consulted for Astellas, Astra Zeneca, Boehringer Ingelheim, Casma, Cytokinetics, Entrada, Janssen/J&J, Merck, Mission Therapeutics, NovMeta, and Pfizer. SMP receives royalties from UpToDate. Copyright: © 2022, Taguchi et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Submitted: January 12, 2022; Accepted: October 5, 2022; Published: December 1, 2022. Reference information: J Clin Invest. 2022;132(23):e158096. https://doi.org/10.1172/JCI158096.
Publisher Copyright:
Copyright: © 2022, Taguchi et al.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Acute kidney injury (AKI) occurs in approximately 13% of hospitalized patients and predisposes patients to chronic kidney disease (CKD) through the AKI-to-CKD transition. Studies from our laboratory and others have demonstrated that maladaptive repair of proximal tubule cells (PTCs), including induction of dedifferentiation, G2/M cell cycle arrest, senescence, and profibrotic cytokine secretion, is a key process promoting AKI-to-CKD transition, kidney fibrosis, and CKD progression. The molecular mechanisms governing maladaptive repair and the relative contribution of dedifferentiation, G2/M arrest, and senescence to CKD remain to be resolved. We identified cyclin G1 (CG1) as a factor upregulated in chronically injured and maladaptively repaired PTCs. We demonstrated that global deletion of CG1 inhibits G2/M arrest and fibrosis. Pharmacological induction of G2/M arrest in CG1-knockout mice, however, did not fully reverse the antifibrotic phenotype. Knockout of CG1 did not alter dedifferentiation and proliferation in the adaptive repair response following AKI. Instead, CG1 specifically promoted the prolonged dedifferentiation of kidney tubule epithelial cells observed in CKD. Mechanistically, CG1 promotes dedifferentiation through activation of cyclin-dependent kinase 5 (CDK5). Deletion of CDK5 in kidney tubule cells did not prevent G2/M arrest but did inhibit dedifferentiation and fibrosis. Thus, CG1 and CDK5 represent a unique pathway that regulates maladaptive, but not adaptive, dedifferentiation, suggesting they could be therapeutic targets for CKD.
AB - Acute kidney injury (AKI) occurs in approximately 13% of hospitalized patients and predisposes patients to chronic kidney disease (CKD) through the AKI-to-CKD transition. Studies from our laboratory and others have demonstrated that maladaptive repair of proximal tubule cells (PTCs), including induction of dedifferentiation, G2/M cell cycle arrest, senescence, and profibrotic cytokine secretion, is a key process promoting AKI-to-CKD transition, kidney fibrosis, and CKD progression. The molecular mechanisms governing maladaptive repair and the relative contribution of dedifferentiation, G2/M arrest, and senescence to CKD remain to be resolved. We identified cyclin G1 (CG1) as a factor upregulated in chronically injured and maladaptively repaired PTCs. We demonstrated that global deletion of CG1 inhibits G2/M arrest and fibrosis. Pharmacological induction of G2/M arrest in CG1-knockout mice, however, did not fully reverse the antifibrotic phenotype. Knockout of CG1 did not alter dedifferentiation and proliferation in the adaptive repair response following AKI. Instead, CG1 specifically promoted the prolonged dedifferentiation of kidney tubule epithelial cells observed in CKD. Mechanistically, CG1 promotes dedifferentiation through activation of cyclin-dependent kinase 5 (CDK5). Deletion of CDK5 in kidney tubule cells did not prevent G2/M arrest but did inhibit dedifferentiation and fibrosis. Thus, CG1 and CDK5 represent a unique pathway that regulates maladaptive, but not adaptive, dedifferentiation, suggesting they could be therapeutic targets for CKD.
UR - http://www.scopus.com/inward/record.url?scp=85143095160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143095160&partnerID=8YFLogxK
U2 - 10.1172/JCI158096
DO - 10.1172/JCI158096
M3 - Article
C2 - 36453545
AN - SCOPUS:85143095160
SN - 0021-9738
VL - 132
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 23
M1 - e158096
ER -